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Abstract
Background: Cervical dysplasia (cervical intraepithelial neoplasia (CIN)) is caused by Human Papillomavirus (HPV)
and is most common in women of reproductive age. Current treatment of moderate to severe CIN is surgical. This
procedure has potential complications, such as haemorrhage, infection and preterm birth in subsequent pregnancies.
Moreover, 15% of women treated for high grade CIN develop residual/recurrent CIN or cervical cancer after surgical
excision. Finally, 75–100% of patients with a residual and recurrent CIN 2–3 lesion are still HPV positive. They could
possibly benefit from an alternative medical treatment, which aims to eliminate HPV.
The primary study objective is to evaluate the effectivity of imiquimod 5% cream compared to treatment with Large
Loop Excision of the Transformation Zone (LLETZ) for recurrent/residual CIN.
Methods/design: This study is a multicentre, non-inferiority randomized single blinded study. The study population
consists of female patients with histological proven residual/recurrent CIN after previous surgical treatment. Four
hundred thirty-three patients will be included in the Netherlands. The first 35 patients will be included in a
pilot study to prove non-futility.
Included patients will be randomized to receive either 5% imiquimod cream or LLETZ treatment. Imiquimod
will be inserted three times a week intravaginally for a period of 16 weeks using a vaginal applicator. Ten
weeks after the end of imiquimod treatment a biopsy will be taken for treatment response. In case of progressive or
stable disease a LLETZ will be performed. At 12 and 24 months after the start of treatment cytology will be taken for
follow up. The LLETZ group will be treated according to the current guidelines. Throughout the study, HPV typing and
quality of life will be tested.
Discussion: Repeated LLETZ in women with residual/recurrent CIN lesions has complications. We would like to
possibly offer alternative treatment in a selected group to avoid these risks. Moreover, we monitor treatment
efficacy, side effects and long-term recurrence rates.
Trial registration: Medical Ethical Committee approval number: NL 53792.078.15. Affiliation: Erasmus Medical Center.
Registration number ClinicalTrials.gov: NCT02669459, date of registration: 27th January 2016.
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Background
Cervical dysplasia is caused by Human Papillomavirus
(HPV) and is most common in women of reproductive
age. Cervical dysplasia is known to be a precancerous
stage of cervical cancer, the fourth most common type
of cancer worldwide in women [1]. Treatment of moder-
ate to severe dysplasia is often still surgical and aimed at
eliminating the affected part of the transformation zone
[2]. There are different type of surgical treatments (Large
Loop Excision of the Transformation Zone (LLETZ), knife
cone biopsy and laser conisation), the success rate is ap-
proximately 90% [3]. Historically, moderate and severe
dysplasia was treated with cold knife biopsy. Nevertheless,
with deep cones, hemorrhage, infection and post proced-
ure stenosis were reported [4]. LLETZ seems to be a good
alternative. This procedure could be performed under
local anesthesia, is cheaper, less painful and seem to have
less short and long term morbidity. Risk of residual dis-
ease is the same compared to cold knife cone [5]. There-
fore, LLETZ is the golden standard for treating cervical
dysplasia nowadays.
Still, there is uncertainty about the effects of LLETZ
on short and long term in terms of recurrence, fertility
and future pregnancy outcomes. Since women diagnosed
with CIN are usually at their reproductive age, the ef-
fects on future fertility and pregnancy are of concern.
Women with a shorter time interval from LLETZ to
pregnancy seem to have an increased risk for spontan-
eous abortion [6]. Furthermore, a recent study described
a higher subfertility rate in patients who underwent cer-
vical surgery [7] Finally, several studies show a higher
risk on preterm delivery and low birth weight [6, 8–11].
Systematic review and meta-analysis reported on LLETZ
for CIN confirm an increased rate of preterm delivery
(<32wks RR 1.98, 95% CI 1.31–2.98; <28wks RR 2.33,
95% CI 1.84–2.94), premature rupture of the membranes
(RR 1.88, 95% CI 1.54–2.29) and low birth weight
(< 2500 g RR 2.48, 95% CI 1.75–3.51) [8, 10]. One study
reported a 10 fold higher risk for preterm deliveries after
more than one conisation procedure in women with cer-
vical dysplasia [12]. The risk of preterm birth could also
be related to the volume of the cervical excision [13, 14].
However this research is performed in patients with one
procedure, volume could be the same factor in patients
with multiple procedures.
Apart from reproductive arguments there is an on-
going debate on the long-term outcome after treatment
with surgical excision. Several studies show a recurrence
rate of CIN 2–3 after treatment of 15–22% within 2 years
[15]. Margin involvement seemed to be a risk factor for
developing residual or recurrent cervical dysplasia [15].
Moreover, even after adequate treatment and follow up
with normal smear results, patients who were treated for
cervical intraepithelial dysplasia seem to have an excessive
risk of cervical cancer compared to patients with normal
primary smear test results [16, 17]. This risk is even
almost 25 times higher in patients with abnormal smear
test results than in patients with normal smear test results
after treatment [18]. Recent studies found that most
women with residual or recurrent disease test positive for
HPV after treatment [19, 20]. Possibly this could be a tool
for risk stratification in the follow up after treatment.
Moreover, treatment failure could be related to the
HPV status. This could raise the question if patients of
this specific group could benefit from a non-invasive
treatment modality to treat HPV and avoid further sur-
gical treatment.
A potential agent in non-invasive therapy is imiquimod
cream. Imiquimod 5% cream is a topical immune response
modifier with indirect antiviral and antitumor properties.
It is prescribed for HPV-associated genital warts, superfi-
cial basal cell carcinoma and actinic keratosis. Studies
showed that it is a safe and effective treatment for usual
type vulvar intraepithelial neoplasia (VIN), which is patho-
physiologically comparable to CIN [21]. Furthermore, imi-
quimod seems also to be effective in primary CIN lesions
[22]. It would also be helpful to determine a model to
predict the responders to imiquimod therapy. This could
select patients for non-ablative treatment.
The Topic 2 trial is a single blinded, randomized
controlled trial with two intervention arms, in which
imiquimod treatment is compared to standard treat-
ment by LLETZ in patients with residual/recurrent
CIN lesions after previous ablative treatment. The
aim of the study is to investigate whether topical
applied imiquimod is effective in the treatment of re-
sidual and recurrent CIN lesions.
Methods
Setting and study population
Patients are recruited at the moment in the Erasmus
Medical Center, Rotterdam and in the Meander
Hospital, Amersfoort, The Netherlands. This takes place
at the outpatient clinic of gynecology. When non futility
is proven after the pilot study, we intend to carry out a
multi-center trial in the future throughout the
Netherlands. Patients can be included if they have histo-
logically confirmed residual or recurrent CIN lesions
(CIN 1–3) after previous ablative treatment at least
6 months before the current diagnosis and have an age
above 18 years. They are excluded if they have adenocar-
cinoma in situ, a history of (micro-) invasive cancer,
hypersensitivity to the substance, immunodeficiency,
pregnancy or lactation and insufficient knowledge of the
English or Dutch language.
Study objectives and outcome measures
The primary study objectives are:
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1. To evaluate the effectivity of vaginal application of
imiquimod 5% in the treatment of recurrent or
persistent CIN. The primary outcome measure is
reduction to normal cytology of the cervix at
26 weeks after start treatment in imiquimod and
LLETZ group.
Secondary study objectives and outcome measures are:
1. To evaluate the effectivity of vaginal application of
imiquimod 5% in the treatment of recurrent/
residual CIN; reduction to absence of dysplasia in
histology at 26 weeks as compared to baseline in
the Imiquimod group.
2. Evaluate of the effect of treatment on HPV DNA
positivity of CIN lesions, by comparison of PCR
HPV-DNA detection at cervical biopsies/cytology
taken at 0 and 26 weeks.
3. Establish the incidence and severity of side effects
of LLETZ and imiquimod therapy.
4. Review the Quality of life (QoL) in patients at 0 and
20 weeks and after 1 year by the following QoL
questionnaires: RAND 36, QLQ-C30 and QLQ-
CX24.
5. Estimate the long term recurrence rate of CIN
lesions measured by reduction to PAP1 by cytology
examination at 6, 12 and 24 months after treatment.
We will request the first outcome taken by the Dutch
screening program for cervical cancer: cytology or
HPV status will be obtained.
Interventions
Patients will receive verbal and written information
about the study procedure. They have to sign an in-
formed consent, where after patients are randomized
into the intervention arm or the standard treatment:
1. Intervention arm: Imiquimod treatment. Patients in
this group have to insert imiquimod 5% cream
intravaginally for 16 weeks.
2. Standard treatment. A LLETZ procedure is performed
according to the current guidelines.
Patients in the imiquimod treatment group will apply
imiquimod 5% cream intravaginally during 16 weeks.
One sachet contains 12,5 mg of imiquimod and is ap-
plied with a vaginal applicator. The application fre-
quency is 3 times a week. Patients get instructions and
administer the cream themselves, before bedtime. The
patients are advised to take an intravaginal shower with
an applicator the next morning in order to remove
cream leftovers, followed by an external shower to re-
move any remains on the vulva. Anti-inflammatory
drugs (paracetamol or NSAID) can be used in case of
mild systemic drug-related side effects. If the local or
systemic side effects persist or are severe, patients are
advised to reduce the frequency of the imiquimod inser-
tion, first twice weekly, subsequently once weekly.
Imiquimod treatment is discontinued for maximum of a
week in case of persistent side effects. In order to pre-
vent pregnancy, patients are advised to use adequate
contraception. Subjects should refrain from vaginal sex-
ual intercourse during the nights that imiquimod is ap-
plied until the vaginal shower the next morning. After
10 weeks a colposcopy is performed to rule out disease
progression. Biopsies are only performed in case of sus-
picion of invasive disease.
In the standard treatment group, patients will undergo
a LLETZ procedure within 4 weeks after the diagnosis.
Excision of macroscopic lesions and the transformation
zone will be achieved by a monopolar loop electrode,
preferably under local anaesthesia.
Treatment efficacy is evaluated at 26 weeks follow-up
for both groups. The Imiquimod group will have a Pap
smear and a colposcopy with diagnostic biopsies. Biop-
sies are performed at the initial CIN lesion site and at
any other suspect site, with a minimum of two. In case
of persistent or progressive disease, surgical excision is
performed. The LLETZ group will have follow-up with
cervical smears at 6, 12 and 24 months according to the
current guidelines.
This study protocol is almost identical to the TopIC-2
study, which is from the same study group. The TopIC-1
study studies the treatment of primary high grade CIN
lesions with imiquimod or LLETZ procedure [22].
Sample size calculation
The regression rate of a second LLETZ procedure is
estimated 63% in a retrospective cohort (data not
published). The regression rate of CIN lesions after
treatment with imiquimod was based upon the only
study reporting on the regression rate after 16 weeks
of imiquimod therapy of primary CIN. This study
showed a regression rate of 73% in patients with pri-
mary CIN lesions [23]. Since the effect could be
lower in patients with residual or persistent CIN, we
estimated the regression rate to be 60%.
To calculate the required sample size in this
two-proportions non-inferiority trial we assume that
the probability of regression is 63% for the standard
(LLETZ procedure) while it is 60% after treatment
with imiquimod.
Using a non-inferiority margin of 10% for the differ-
ence in proportions and a significance level (alpha) of
5%, a sample size of 174 per group is required to obtain
a power of at least 80%. Allowing for 20% loss to
follow-up the total required sample size is 433.
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Because the uncertainty in the assumptions an interim
analysis for futility will be performed by the Data Moni-
toring Committee (DMC) as soon as the primary out-
come is available for 35 patients. This interim analysis is
based on predictive power. That is the predicted prob-
ability of being able to prove non-inferiority given the
results at the interim analysis. When the predictive
power at this point is below 20% the trial will be stopped
due to futility. Of course the DMC can always stop the
trial due to safety concerns. The trial will never be
stopped prematurely for efficacy so no alpha-adjustment
is made.
Randomization
Randomization is performed by use of a computerized
randomization tool, to prevent selection and alloca-
tion bias.
Blinding
The study is single blinded: the pathologists evaluating
cytological and histological samples are blinded with
respect to the intervention.
Data collection
The coded data will be stored both on paper and in an
electronic database. A digital case report form (e-CRF) is
used. The data is accessible only to the principal and co-
ordinating investigator. The following data are recorded:
Baseline (all patients)
– Patient characteristics: age, medical history, desire to
have children, smoking, sexual behaviour.
– HPV genotype
– Quality of life for both treatment groups.
6 weeks follow-up
– Adverse effects of imiquimod treatment: patient
reported side effects and side effects noticed at
clinical investigation.
– Adverse effects of LLETZ treatment: patient reported
side effects.
10 weeks follow-up
– Treatment compliance: amount of applied doses of
imiquimod for the imiquimod group.
– Adverse effects of imiquimod treatment: patients
reported side effects and side effects noticed at
clinical investigation.
– Colposcopy with biopsies to determine progressive
or invasive disease in the imiquimod group.
16 weeks follow-up
– Adverse effects of imiquimod treatment: patient




– Cervical cytology and HPV genotype.
– Quality of life
– Determination of grade of cervical dysplasia
– Treatment compliance: amount of applied doses of
imiquimod.
– Adverse effects of imiquimod treatment: patients
reported side effects and side effects noticed at
clinical investigation.
LLETZ group
– Cervical cytology and HPV genotype.
– Quality of life
– With abnormal PAP smear, determination of grade
of cervical dysplasia.
12 and 24 months follow-up
– Cervical cytology outcomes for all treatment groups,
including HPV genotyping.
Statistical methods
Analysis will be done according to the intention to treat
principle and the non-inferiority principle to show that
imiquimod is not worse than an existing treatment
(LLETZ). To investigate efficacy we will perform a per
protocol analysis (although this is not the primary out-
come of the study). The primary outcome is the differ-
ence between the probability of regression in the LLETZ
and the imiquimod arms. The expected difference
(LLETZ-imiquimod) will be calculated together with the
95% Aggresti confidence interval. If the upper bound of
the interval lies below the non-inferiority margin of 10%
non-inferiority of the imiquimod treatment is assumed
to be proved. Logistic analysis of potential confounders
(age at diagnosis, CIN grade, number of previous
treatments, smoking, HPV-subtype) will be performed.
Analysis will be based on intention to treat protocol.
The prevalence and severity of side effects of imiqui-
mod and LLETZ treatment, as documented according to
Common Terminology Criteria for Adverse Events
guidelines, will be presented as proportions and means
with 95% confidence intervals. Differences in the rates of
overall side-effects and severe side-effects between the
imiquimod and LLETZ groups will be tested with a
chi-square test. Disease recurrence rates, defined by
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abnormal cervical cytology, after 6, 12 and 24 months
will be evaluated in adequately treated patients by use of
multiple logistic regression analysis, after adjustment for
age at diagnosis, CIN grade, smoking sexual behavior
and HPV subtype.
Withdrawal of individual subjects and replacement
A study subject can stop the study at any time without
explanation, this will have no consequences. The investi-
gator can decide to withdraw a subject from the study
for urgent medical reasons, non-compliance with the
study procedures or pregnancy. There will be no re-
placement for withdrawn individuals. In principal a
LLETZ will be performed, since this is still the stand-
ard treatment for patients with recurrent or persistent
CIN lesions.
Ethical considerations and dissemination
The standards outlined in the Declaration of Helsinki
are guidelines for the study. Before the start of the study
there was approval of the ethics committee. There is a
data management safety board throughout the study.
We will record adverse events and reported them to
local protocol. We will be offering the study results for
publication in international medical journals. If the sub-
ject agreed on this, study results will be communicated
to trial participants by mail.
Discussion
The development of a non-surgical treatment modality
for residual and recurrent CIN lesions will lower the
amount of LLETZ procedures for this indication and
complications as a result of surgical intervention.
Evidence shows that 15–22% of high-grade CIN lesions
will persist or recur after 2 years and that patients after
treatment for high grade CIN lesions will remain at higher
risk for cervical cancer in the future. Based on earlier
studies, we hypothesize that at least 50% of patients with
high grade CIN will benefit from immunotherapy with
imiquimod. The current study aims to test the treatment
effectivity, while also assessing the clinical applicability of
imiquimod treatment by documentation of side effects
and quality of life associated with treatment.
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